Supercharged immune cells target stubborn lymphoma
NCT ID NCT02690545
Summary
This study is testing a new cell therapy for people whose Hodgkin's or Non-Hodgkin's lymphoma has come back or hasn't responded to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to better target cancer cells, and then infuse them back into the patient. The main goals are to find a safe dose and see if this therapy can keep the cancer from progressing for two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.